Anupam Rasayan completes 48.2% controlling stake acquisition in Bliss GVS Pharma
As filed · Anupam Rasayan India Limited has informed the Exchange regarding a press release titled "Anupam Rasayan Concludes Acquisition of Bliss GVS Pharma, Marks Third Strategic Step Towards Building an Integr
What happened
FactAnupam Rasayan paid ₹299 per share to complete the acquisition of a 48.2% controlling stake in Bliss GVS Pharma through its wholly owned subsidiary, Mates Visa Consultancy. The transaction was funded by a ₹300 crore term loan and approximately ₹1,450 crore of non-controlling, non-voting instruments; the company expects the combined platform to have pro-forma revenue above ₹4,000 crore and EBITDA of approximately ₹834 crore.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
Scale
- 17.9% of FY26 revenue
₹300 Cr stated in the filing against ₹1,675.57 Cr revenue (FY26, standalone)
Source: financial_facts · exchange_table
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
ContradictedMargins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix.
On profitability, the company reported consolidated EBITDA margins of ~19.5% in Q2 FY26 and ~25.5% for H1 FY26.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- we should be below 200, around 180 days or below is the management's focus and target here. (management committed by FY27)
- we expect that in the near-term we should be going towards 220, 200. (management committed by FY27)
Evidence
- Anupam Rasayan India Limited has informed the Exchange regarding a press release titled "Anupam Rasayan Concludes Acquisition of Bliss GVS Pharma, Marks Third Strategic Step Towards Building an Integrated Global Pharma Platform".(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q2 FY26
- Earlier statement · Q3 FY26
How CapitSignal classified this
- Reasoning:
- The completed acquisition extends Anupam Rasayan into finished dosage formulations and creates a larger integrated chemicals and pharmaceuticals platform. The low stated capacity utilisation at Bliss GVS indicates potential growth headroom, while the funding structure adds term-loan financing and substantial outside-investor capital.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%